Skip to content
Optionomics Free · No account needed

Earnings analysis · 10-Q

MBIO earnings analysis

Filed May 5, 2026 · Our reading of the company's report

The latest report

Mustang Bio reported a challenging fourth quarter, with no revenue earned and a net loss of $955,000. Operating expenses have increased compared to the prior period, primarily due to a rise in research and development…

Read full summary

Mustang Bio reported a challenging fourth quarter, with no revenue earned and a net loss of $955,000. Operating expenses have increased compared to the prior period, primarily due to a rise in research and development costs. The company continues to face regulatory hurdles and must regain compliance with Nasdaq listing rules.

Read the original on SEC.gov

Reported figures

Earnings per share
$-0.07

What stood out

  • Increased R&D Expenses

    R&D expenses rose approximately $1.1 million from $(1.0) million to $0.2 million year-over-year.

  • Continuing Net Losses

    Net loss increased significantly from $(153,000) in Q1 2025 to $(955,000) in Q1 2026.

  • Regulatory Compliance Deadline

    Mustang has a 180-day grace period until October 12, 2026, to regain compliance with Nasdaq's bid price requirement.

  • Material Weakness Identified

    Accumulated deficit reached $399.6 million as of March 31, 2026, indicating ongoing financial difficulties.

  • Cash Position

    Cash and cash equivalents decreased to $16.3 million compared to higher balances seen in previous quarters.

  • Operating Cash Flow Improvement

    Net cash used in operating activities decreased from $(1.4 million) in Q1 2025 to $(1.0 million) in Q1 2026.

What to watch

  • Risk of Delisting

    The company is at risk of being delisted from Nasdaq if it fails to comply with the $1.00 closing bid price requirement.

  • Regulatory Approval Uncertainty

    There is no guarantee that any of Mustang's product candidates will receive regulatory approval.

  • Ongoing Financial Losses

    Continued operating losses are anticipated, raising concerns about the company's long-term viability.

Management's outlook

Management anticipates continued operating losses and negative cash flows for the foreseeable future.

This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.